Michael R Charlton
Overview
Explore the profile of Michael R Charlton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
3430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Charlton M, Alam A, Shukla A, Dashtseren B, Lesmana C, Duger D, et al.
J Gastroenterol
. 2020 Jul;
55(9):811-823.
PMID: 32666200
Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV) infection. The use of guideline-recommended nucleos(t)ide analogs with high barrier to resistance, such as entecavir (ETV), tenofovir disoproxil...
12.
Micic D, Oto A, Charlton M, Benoit J, Siegler M
N Engl J Med
. 2020 May;
382(19):1844-1849.
PMID: 32374966
No abstract available.
13.
Peeraphatdit T, Wang J, Odenwald M, Hu S, Hart J, Charlton M
Hepatology
. 2020 Mar;
72(1):315-329.
PMID: 32167613
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies. The advent of ICIs has been a major...
14.
Gane E, Charlton M, Mohamed R, Sollano J, Tun K, Pham T, et al.
J Viral Hepat
. 2019 Dec;
27(5):466-475.
PMID: 31785182
Asia has an intermediate-to-high prevalence of and high morbidity and mortality from hepatitis B virus (HBV) infection. Optimization of diagnosis and initiation of treatment is one of the crucial strategies...
15.
16.
Charlton M, Gane E, Shukla A, Dashtseren B, Duger D, Muljono D, et al.
Transplantation
. 2018 Oct;
103(4):733-746.
PMID: 30335692
Background: The population of Asia exceeds 4.4 billion people. Chronic hepatitis C virus (HCV) infection in Asia is characterized by specific distribution of genotypes, lack of access to specific therapeutic...
17.
Jayakumar S, Middleton M, Lawitz E, Mantry P, Caldwell S, Arnold H, et al.
J Hepatol
. 2018 Oct;
70(1):133-141.
PMID: 30291868
Background & Aims: Non-invasive tools for monitoring treatment response and disease progression in non-alcoholic steatohepatitis (NASH) are needed. Our objective was to evaluate the utility of magnetic resonance (MR)-based hepatic...
18.
Sundaram V, Jalan R, Ahn J, Charlton M, Goldberg D, Karvellas C, et al.
J Hepatol
. 2018 May;
69(3):617-625.
PMID: 29709681
Background & Aims: Acute-on-chronic liver failure (ACLF) is a syndrome of systemic inflammation and organ failures. Obesity, also characterized by chronic inflammation, is a risk factor among patients with cirrhosis...
19.
Wongjarupong N, Negron-Ocasio G, Chaiteerakij R, Addissie B, Mohamed E, Mara K, et al.
World J Gastroenterol
. 2018 Mar;
24(12):1321-1331.
PMID: 29599607
Aim: To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma (HCC) patients after liver transplant. Methods: BALAD score and BALAD-2 class are...
20.
Younossi Z, Loomba R, Anstee Q, Rinella M, Bugianesi E, Marchesini G, et al.
Hepatology
. 2017 Dec;
68(1):349-360.
PMID: 29222917
Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis, nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. The majority of NAFLD subjects do not have NASH and do...